Therefore, our results underscore the potential of CBX3 as a new biomarker for the noninvasive survival and diagnosis of ccRCC and offers a promising therapeutic target for the treatment of affected individuals. The gene discussed is CBX3; the disease is nonpapillary renal cell carcinoma.